Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novantrone mitoxantrone inhibitor of DNA replication: Phase III data; marketed to treat hormone refractory prostate cancer and nonlymphocytic leukemia

IMNX reported preliminary results of a 194-patient Phase III study conducted in Europe (see Technology Briefing, BioCentury Part I). Patients received

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers